alexa Potential Roles Of Cancerous Immunoglobulins In Cancer Immunology
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Gregory Lee
ScientificTracks Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.017
Expressions of immunoglobulins essential for growth/proliferation of cancer cells have been known for decades. However, the detailed mechanisms of action and their roles in the immunity of cancer cells are not fully understood. RP215 is a monoclonal antibody generated against cancer cell extract and was shown to react mainly with a carbohydrate-associated epitope in the heavy chains of immunoglobulins on the surface of all human cancer cells, but not in normal immune cells. Through years of studies with RP215 as the unique probe, it is now established that RP215 and goat anti-human IgG act biosimilarly on cultured cancer cells, including induced apoptosis, complement-dependent cytotoxicity as well as gene regulations. Both were shown to regulate genes involved in the growth/proliferation as well as the innate immunity of cancer cells with high correlations. Previous studies also indicated that cancerous immunoglobulins are expressed with molecular mechanisms completely different from those of normal immune cells in our human body. Therefore, the expressed cancerous immunoglobulins maybe playing key roles to neutralize circulating ?antigen? within the body for immune protection of cancer cells. Both normal and cancer immune systems can operate independently in our body. We believe that a better understanding about the underline mechanisms of cancerous immunoglobulins may lead to a more realistic strategy for cancer immunotherapy in humans.
Gregory Lee upon completion of his PhD degree in Biophysical Chemistry at California Institute of Technology in 1972 joined UCSD as a NIH Postdoctoral Fellow to carry out pioneer work on general ligand affinity chromatography. In 1976, he studied enzymology and biochemical genetics at the National Institute of Health and in 1981, he was appointed as a Professor and Director of the Andrology Laboratory at the University of British Columbia. During the last two decades, he has created numerous monoclonal antibodies for diagnostic and therapeutic applications in human health care, including RP215 and GHR106 for potential use as anti-cancer drugs. He has been serving as an editorial board member for Journal of Cancer Science and Therapy, American Journal of Cancer Review, American Journal of Cancer Science, and Journal of Biochemistry and Physiology .
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version